Transcriptomics

Dataset Information

0

Engineered CD47 protects T cells for enhanced antitumor immunity


ABSTRACT: Adoptively transferred T cells and agents designed to block the CD47/SIRPalpha axis are promising cancer therapeutics that activate distinct arms of the immune system. We administered anti-CD47 with adoptively transferred T cells with the goal of enhancing antitumor efficacy but observed rapid macrophage-mediated clearance of T cells expressing chimeric antigen receptors (CARs) or engineered T cell receptors, which abrogated therapeutic benefit. anti-CD47 mediated CAR T clearance was potent and rapid enough to serve as an effective safety switch. To overcome this challenge, we engineered a CD47 variant (47E) that engaged SIRPalpha and provided a “don’t-eat-me” signal that was not blocked by anti-CD47 antibodies. TCR or CAR T cells expressing 47E were resistant to clearance by macrophages following anti-CD47, and mediated significant, sustained macrophage recruitment into the TME. Although many of the recruited macrophages manifested an M2-like profile, the combined therapy synergistically enhanced antitumor efficacy. This work identifies macrophages as major regulators of T cell persistence and illustrates the fundamental challenge of combining T cell directed therapeutics with those designed to activate macrophages. It further delivers a therapeutic approach capable of simultaneously harnessing the antitumor effects of T cells and macrophages that manifests enhanced potency against solid tumors.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE261475 | GEO | 2024/03/13

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-07-19 | MSV000095386 | MassIVE
2022-11-25 | GSE197111 | GEO
2023-09-29 | GSE214140 | GEO
2021-01-27 | GSE148948 | GEO
2021-01-27 | GSE148947 | GEO
2022-09-29 | GSE156106 | GEO
2024-06-19 | GSE244548 | GEO
2017-10-03 | GSE104512 | GEO
2022-12-09 | GSE201825 | GEO
2021-10-28 | GSE183489 | GEO